ABOS - התחייבויות לטווח ארוך להון acumenpharm.com

Acumen Pharmaceuticals (ABOS) is establishing a closed ecosystem for targeted Alzheimer's disease therapy, recruiting patients through US centers under FDA supervision. In partnership with institutes, the company is developing methods to protect neurons from toxic proteins. The long-term debt-to-equity ratio reflects a balance of liabilities, where the parameter value equals 0.18. The development of immunotherapy will ensure multi-year patent profits driven by lifelong patient treatment.

The long-term debt-to-equity ratio determines the degree of financial leverage and the stability of the balance sheet structure. An increase in this metric signals a rising credit burden, while a minimum value may indicate an underutilization of borrowed funds. By analyzing the historical trend of long-term debt to equity, an investor assesses the risk of bankruptcy. For Acumen Pharmaceuticals (ABOS), this is critical due to a single-product dependence on Alzheimer's disease drug trials. High debt leverage in the absence of revenue could lead to a collapse should clinical trials fail.